China To Issue New Rules On Adverse Event Reporting To Enhance Surveillance
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA is accepting public comments until July 27 on its new draft regulation for reporting adverse events. Posted on the agency's website, the new measure aims to tighten surveillance on adverse event reporting to enhance safety and better control risk, the agency said